Alfasigma to seek regulatory approval following OLINGUITO study success
Category: News
CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy
CHMP recommends authorization for LP.8.1-targeting vaccine ahead of 2025-2026 season
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]
Collaboration aims to advance next-generation therapeutics and vaccines
First patient dosed in phase 1b/2a study of procizumab
Irish biotech’s germ-free egg platform could help close global shortfall
GlueSEEKER enables rational design of targeted protein degraders
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients